Depression

Salt Lake City, UT

110 Depression Trials near Salt Lake City, UT

Power is an online platform that helps thousands of Depression patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Heat Therapy + Cold Water Plunge for Depression

Edwards, Colorado
This study will recruit 112 medically healthy adults (aged 18-65) currently experiencing depressive symptoms to be randomized to receive either a single Whole Body Hyperthermia (heat therapy) treatment or a Whole Body Hyperthermia treatment followed by a cold water plunge. Participants will complete a baseline assessment of their depressive symptoms as well as 1-week and 2-week post-treatment followup assessments.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65

112 Participants Needed

Azetukalner for Depression

Boise, Idaho
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

450 Participants Needed

SP-624 for Depression

Meridian, Idaho
This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.

Trial Details

Trial Status:Recruiting
Age:18 - 65

456 Participants Needed

Family Spirit Programs for Mental Health Issues

Shiprock, New Mexico
This project addresses the disproportionate morbidity and mortality associated with mental and behavioral health problems in American Indian and Alaska Native communities. Access to culturally competent and effective behavioral health services is limited in many of these communities. The investigators aim to address this gap by testing the effectiveness of a trans-diagnostic secondary prevention program, Family Spirit Strengths (FSS) that can be embedded within home visiting services. The FSS program is a skills-based program that incorporates elements of evidence-based practice, the Common Elements Treatment Approach (CETA), and materials informed and developed based on an Indigenous advisory group. The FSS program aims to help participants build self-efficacy and coping skills, as well as build stronger connections to others, the participants' community, and cultural resources. The investigators will use a randomized controlled trial, whereby half of the participants will receive FSS and the other half will receive an evidence-based nutrition education program. The investigators' study is grounded in participatory processes and led by a team of Indigenous and allied researchers.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:14+
Sex:Female

188 Participants Needed

Stimulant Medication for ADHD

Laramie, Wyoming
The investigators will examine the acute effects of stimulant medication on executive functioning. The rationale for the proposed study is to examine the efficacy of stimulants for college students with ADHD and help prevent stimulant misuse among college students without ADHD. The working hypothesis is that stimulants, compared to baseline and placebo conditions, will improve executive functioning for college students with ADHD but not for college students without ADHD. Improvements on executive functioning measures (e.g., CPT-IP, Spatial Span) will be examined through 2 (ADHD vs. non-ADHD) x 3 (Baseline, Placebo, Stimulant) repeated measures ANOVAs. Follow-up analyses will include paired comparisons. Expected outcomes are to confirm these hypotheses and demonstrate the need for further study of stimulants. If confirmed, the results will provide pilot data for a larger NIH grant proposal aimed at further examining the acute effects of stimulants (i.e., improved cognitive functioning with stimulants) and comparing them to the acute effects of physical exercise (i.e., improved cognitive functioning immediately after exercise). The investigators expect this outcome to have an important positive impact because it can help support stimulant medication as an effective treatment for college students with ADHD (DuPaul et al., 2012). Additionally, demonstration that stimulants do not improve executive functioning for college students without ADHD can be used to help prevent and discourage stimulant misuse and diversion on college campuses (Hartung et al., 2013).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 29

40 Participants Needed

Psilocybin for Trauma

Bozeman, Montana
This trial tests the use of psilocybin microdosing to help patients with chronic illnesses like PTSD and depression. Psilocybin, found in certain mushrooms, helps the brain form new pathways, reducing negative thoughts. This approach targets patients who don't respond well to traditional treatments. Psilocybin has shown promise as a treatment for major depressive disorder and was designated as breakthrough therapy by the FDA.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 1
Age:21 - 99

30 Participants Needed

Cannabidiol for Older Adult Cannabis Users

Boulder, Colorado
Cannabis use increased 10 fold among adults over the age of 65 between 2014 and 2016 but very little data exists on the extent of their harmful effects on health and behavior. The overarching goal of this project is to test a novel harm reduction strategy in which older individuals who seek to use cannabis for pain, anxiety or mood problems (depression/anxiety) will be randomly assigned to one of three conditions in an 8 week randomized controlled trial: hemp-derived CBD+THC, hemp-derived CBD-THC, or placebo. This work has the ability to directly inform individual choices regarding the use of cannabis products among older adults, and direct policy decisions regulating cannabis formulations on the legal market.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:60+

385 Participants Needed

Palliative Care Intervention for Advanced Cancer

Boulder, Colorado
Adults diagnosed with metastatic cancer commonly experience depression and anxiety symptoms, which can interfere with advance care planning. This randomized clinical trial evaluates a novel, piloted, primary palliative care intervention that addresses advance care planning and psychosocial needs of patients with metastatic cancer. The intervention focuses on patients with elevated anxiety and depression (anx/dep) symptoms-those with highest psychosocial needs who may be at greatest risk for advance care planning non-completion. The intervention is founded on an evidence-based intervention approach known as Acceptance and Commitment Therapy (ACT) that reduces distress and promotes behavior change through theory-driven mechanisms. In the proposed randomized trial, M-ACT will be compared to a usual care control condition. The study will also assess the association between advance care planning and anx/dep symptoms, thereby informing the critical practice question of whether anx/dep symptoms should be addressed concurrently with advance care planning. The study will enroll patients with Stage IV solid tumor cancer (N=240) within Rocky Mountain Cancer Centers, randomized 1:1 to M-ACT or usual care. The study aims to: 1) Evaluate the hypothesis that M-ACT will increase advance care planning completion (primary outcome) and sense of life meaning, and reduce anx/dep symptoms and fear of dying relative to usual care control. 2) Assess the association between anx/dep symptoms and advance care planning at baseline and over time, testing the hypothesis that decreases in anx/dep symptoms at post- intervention will be associated with increases in advance care planning at follow-up. 3) Assess M-ACT's hypothesized mechanisms to specify how the intervention works (exploratory aim). Given their advance care planning and psychosocial needs, and poor access to palliative care, rigorously investigating M-ACT has the potential to benefit community patients with metastatic cancer and to advance palliative care science by addressing gaps in novel approaches, foundational knowledge, and the scalable delivery of palliative care. Note: Due to the coronavirus pandemic, the in-person group component of M-ACT has currently been shifted to an online group format.
No Placebo Group

Trial Details

Trial Status:Recruiting

240 Participants Needed

Mindfulness-Based Therapy for Depression

Fort Collins, Colorado
Rates of type 2 diabetes (T2D) in adolescents have escalated. Adolescent-onset is associated with greater health comorbidities and shorter life expectancy than adult-onset T2D. T2D is preventable by decreasing insulin resistance, a physiological precursor to T2D. T2D prevention standard-of-care is lifestyle intervention to decrease insulin resistance through weight loss; yet, this approach is insufficiently effective in adolescents. Adolescents at risk for T2D frequently experience depression, which predicts worsening insulin resistance and T2D onset, even after accounting for obesity. Mindfulness-based intervention (MBI) may offer a targeted, integrative health approach to decrease depression, and thereby, ameliorate insulin resistance in adolescents at risk for T2D. In a single-site, pilot randomized controlled trial (RCT), we established initial feasibility/acceptability of a 6-week group MBI program, Learning to BREATHE, in adolescents at risk for T2D. We demonstrated feasible single-site recruitment, randomization, retention, protocol adherence, and MBI acceptability/credibility in the target population. Our preliminary data also suggest MBI may lead to greater reductions in stress-related behavior, vs. CBT and a didactic/health education (HealthEd) control group. The current study is multisite, pilot RCT to test multisite fidelity, feasibility, and acceptability in preparation for a future multisite efficacy trial that will have strong external validity, timely recruitment, and long-term follow-up. Adolescents (N=120) at risk for T2D will be randomized to MBI vs. CBT vs. HealthEd and followed for 1-year. Specific aims are to: (1) test multisite fidelity of training and implementation of 6-week group MBI, CBT, and HealthEd, to teens at risk for T2D; (2) evaluate multisite feasibility/acceptability of recruitment, retention, and adherence for an RCT of 6-week group MBI, CBT, HealthEd with 6-week and 1-year follow-up; and (3) modify intervention training/implementation and protocol procedures in preparation for a future, fully-powered multisite efficacy RCT.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Age:12 - 17

120 Participants Needed

CBT + Exercise for Diabetes Prevention in Adolescents

Fort Collins, Colorado
The investigators are doing this study to learn more about how to prevent type 2 diabetes in teenage girls. The purpose of this study is to find out if taking part in a cognitive-behavioral therapy group, exercise training group, or a combination of cognitive-behavioral therapy and exercise training groups, decreases stress, improves mood, increases physical activity and physical fitness, and decreases insulin resistance among teenagers at risk for diabetes.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:12 - 17
Sex:Female

300 Participants Needed

Solriamfetol for Depression

Las Vegas, Nevada
This trial is testing solriamfetol, a medication that may help improve symptoms of depression. It targets adults with major depressive disorder (MDD) who do not have psychotic features. Solriamfetol works by affecting brain chemicals involved in mood regulation, potentially helping to improve mood and reduce depression symptoms.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65

300 Participants Needed

NMRA-335140 for Depression

Las Vegas, Nevada
This trial is testing a new medication called NMRA-335140 to see if it helps people with major depressive disorder. It includes participants who have no safety concerns. The medication aims to improve mood by affecting brain chemicals.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65

650 Participants Needed

AXS-05 for Depression

Las Vegas, Nevada
This trial is testing AXS-05, a new medication, to see if it can prevent depression from returning in people who have already improved with it. The study focuses on those with major depressive disorder and aims to maintain their balanced brain chemicals to keep them feeling better. AXS-05 (a combination of dextromethorphan and bupropion) has shown positive results in previous trials for major depressive disorder.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 65

350 Participants Needed

ABX-002 for Depression

Las Vegas, Nevada
The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant. This is a double-blind, placebo-controlled, 2-arm, parallel-group, Phase 2 study, randomized 1:1 (ABX-002: placebo). The study will include the following stages: 1. Screening, Treatment, and Follow-Up ; approximately 35 days 2. 42-day Treatment Period 3. 2-week post dose Safety Follow-up Period

Trial Details

Trial Status:Recruiting
Age:18 - 65

230 Participants Needed

NORA520 for Postpartum Depression

Las Vegas, Nevada
This trial is testing a drug called NORA520 to see if it can help women with severe postpartum depression. The study will check how well the drug works, its side effects, and how much of it gets into the blood and breastmilk. Women in the study will take the drug for a short period.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 45
Sex:Female

90 Participants Needed

Engage Therapy for Late-Life Depression with Executive Dysfunction

Las Vegas, Nevada
Although there are an increasing number of mental health treatment adaptations for older adults, there are still a number of factors to consider when making these adaptations. Cognitive decline is one such factor that places significant burden on older adults and can interfere with traditional mental health therapies. Engage is a behavioral treatment approach that has shown to be effective in treating late life depression. The investigators are testing the feasibility of Engage as a treatment method for late life depression in older adults with cognitive decline. The objective is to corroborate Engage as an alternative late life depression treatment method for a sub-population of older adults with cognitive decline. Cognitive decline poses a unique mental health treatment barrier that is often over looked in younger populations. With a relatively higher prevalence of cognitive decline in older adulthood, it is imperative that a feasible mental health treatment program that can be effective in the presence of cognitive decline.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:60+

20 Participants Needed

Escitalopram + Brexpiprazole for Depression

Cheyenne, Wyoming
This is a study that will test a predictive biomarker algorithm based on results from a previous study. The goal of this study is to integrate clinical, imaging, EEG, and molecular data across 8 sites to predict treatment outcome for patients experiencing a major depressive episode (MDE).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 65

400 Participants Needed

Zelquistinel for Depression

Denver, Colorado
The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The main questions it aims to answer are: Does GATE-251 reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no GATE-251)? What medical problems are observed in participants who take GATE-251? Participants will take one tablet of GATE-251 or placebo every week for 6 weeks. Participants will visit the clinic every week of the 6 week period to have the severity of their depression evaluated.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 64

164 Participants Needed

Parenting Skills Group for Postpartum Depression

Denver, Colorado
The goal of this longitudinal study is to study the effects of a parenting skills group (Circle of Security Parenting, aka COSP) in mothers with postpartum depression. The main questions it aims to answer are: * Will changes in methylation of the OXTR rs53576 be apparent in mother and/or infant after having gone through the 8-week COSP program? * Will COSP participation be associated with improved symptoms of postpartum depression (over and above standard care), attachment style, and relational characteristics of the mother-infant dyad? * Will COSP participation be associated with changes in social behavior in the infant, and if so, do they persist throughout childhood? Participants will * Participate in an 8-week COSP program delivered remotely via Zoom. * Provide buccal swabs (mother and infant) to assess changes in methylation of OXTR rs53576 pre- versus post-intervention. * Complete a series of assessment questionnaires delivered remotely. * Videotape a play-based assessment in their home. * Receive infant developmental testing Researchers will compare characteristics of waitlist controls to those participating in the COSP program at the mid-way point of the program to see if the two groups differ.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 50
Sex:Female

750 Participants Needed

In-Person vs. Virtual Therapy for Postpartum Depression

Denver, Colorado
The goal of this clinical trial is to test whether an established preventive intervention (group interpersonal therapy) delivered virtually shows the same benefits for preventing postpartum depression as it does when delivered in person.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Sex:Female

900 Participants Needed

Why Other Patients Applied

"I've used SSRIs (Lexapro, Celexa) and they helped a bit but also, truthfully, they've had pretty serious sexual side effects. Depression was already hurting my marriage, and now these drugs continue to paralyze my it. I've heard that psilocybin-based treatments typically have no sexual side effects... I think a clinical trial will let me try safely."

LN
Depression PatientAge: 44

"I've been through a substance abuse program three times. Clearly, it's not working. I need to try something totally different and new to deal with my depression (plus alcohol usage) once and for all. I did some research on psilocybin and want to try."

QP
Depression PatientAge: 55

"I have tried several different drugs and nothing seems to help really. I'm hoping this trial could give me my life back. I haven't tried anything like psilocybin yet... fingers crossed."

MT
Anxiety PatientAge: 59

"I’m ready to move on with my life. I did a poor job bouncing back from COVID (dealing with a disability). I'd already had a PTSD diagnosis after my spouse died. These past few years have been tough and I'd like to feel like I'm alive again. I need help getting out of this phase."

FY
Depression PatientAge: 60

"I had a serious spinal cord injury four years ago, and my entire life turned upside down. I lost everything including a 10 year relationship. I became handicapped and part of that handicap is a mental handicap or I just can’t seem to find my happiness anymore. I go to events where everybody’s laughing, smiling, dancing, and having a good time, and I seem to just sit there like a bump on log. It feels like my spirit is broken. I want to feel happiness and motivation for life again."

YX
Depression PatientAge: 76

Health Screening and Referral for Premature Birth

Denver, Colorado
Up to a quarter of the families with preterm infants have unmet social needs, such as housing or job insecurity, which represent adverse social determinants of health (SDOH). Preterm infants are especially vulnerable to the social conditions they grow up in, with sustained impacts on function across multiple organ systems. The goal of this study is to translate an established model of SDOH screening and referral from the outpatient setting to the NICU, thereby maximizing the potential to offset the effects of adverse SDOH on vulnerable mother-preterm infant dyads.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Sex:Female

882 Participants Needed

BEET Program + CBT for Type 2 Diabetes and Eating Disorders

Denver, Colorado
Disordered eating behaviors (DEBs, e.g., binge eating or restrictive eating) can significantly impact type 2 diabetes (T2D) self-management and engagement in treatment for diabetes. Managing DEBs is a treatment component in diabetes self-management; however, it is not often the primary focus, and trained behavioral health providers are inconsistently involved in comprehensive diabetes management. This study plans to pilot two behavior change programs for disordered eating in T2D and gather information on factors that predict successful adoption and implementation in real-world clinical settings.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:18 - 65

80 Participants Needed

Hormonal Contraceptives for Depression

Aurora, Colorado
Purpose of this study: The purpose of this study is to learn more about how hormonal oral contraceptives affect brain processes and emotional wellbeing. Procedures: If participants agree to participate, the following will happen: 1. Eligibility visit (remote screening session) 2. If participants are eligible to participate in the study, they will be placed in one of two groups. If they are in the first group, they will be asked to take an oral contraception pill ("study drug") every day for 21 days. If they are in the second, they will take a placebo every day for 21 days. A placebo is a pill that looks like medicine but is not real and will have no medical effect on participants. Participants will not get to choose which group they are in, nor will they be told which group they are in. 3. During the three-week period in which participants will take either the study drug or placebo, they will be asked to complete daily check-in surveys on their computer or mobile device. 4. Participants will be asked to attend two additional visits over the course of about three weeks. At these visits, participants will be asked to undergo a urine drug screen, a blood draw, and a magnetic resonance imaging (MRI). They will also be asked to complete behavioral questionnaires.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 45
Sex:Female

144 Participants Needed

Cognitive Behavioral Therapy for Depression and Suicide Prevention

Aurora, Colorado
This study plans to learn more about the use of one of two self-guided online cognitive behavioral therapy courses. One is focused on symptoms of depression and one is focused on history of suicidal thoughts and behaviors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

472 Participants Needed

Cannabis for Palliative Care in Cancer

Aurora, Colorado
Many cancer patients suffer from pain, sleep, and mood problems and are using cannabis to relieve these symptoms. Cannabis may provide such relief but may also produce negative side effects including cognitive impairment, an especially problematic issue for cancer patients, indicating more research on cannabis use in the cancer context is required. In this endeavor, the present study seeks to compare the use of hemp-derived CBD (Cannabidiol) with and without THC (Delta-9-tetrahydrocannabinol) versus placebo on measures of sleep, pain, mood, subjective and objective cognitive functioning, and quality of life within 185 cancer patients.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:25+

185 Participants Needed

Group Therapy for Depression in Teens with Type 2 Diabetes

Aurora, Colorado
The main purpose of this study is to compare a group-based interpersonal psychotherapy (IPT) program and a Type 2 Diabetes education program to determine if there are differences in depression levels, diabetes distress, and glycemic control in adolescents with Type 2 Diabetes.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:12 - 17

50 Participants Needed

Pramipexole vs Escitalopram for Depression in HIV

Aurora, Colorado
A phase II, randomized, open-label, two-arm clinical trial evaluating the safety and efficacy of pramipexole extended release (ER) versus escitalopram for the treatment of major depressive disorder (MDD) and comorbid MDD with mild neurocognitive disorder (MND) in persons with HIV (PWH). Participants will be assessed comprehensively and briefly at intercurrent visits to monitor for toxicity, response to therapy, and to assess for dose changes. An optional sub-study to evaluate treatment impact on the cerebrospinal fluid (CSF) profile will be conducted in a subset of 36 participants.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 2

186 Participants Needed

Psilocybin for Depression

Aurora, Colorado
The purpose of this study is to evaluate the efficacy of psilocybin on the symptom of anhedonia in individuals with treatment-resistant major depressive disorder.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:21 - 75

40 Participants Needed

Cognitive Behavioral Therapy for Depression and Insulin Sensitivity in Adolescents

Aurora, Colorado
There has been a rise in type 2 diabetes (T2D) rates in adolescents, disproportionately in girls from disadvantaged racial/ethnic groups. This group of girls also is at heightened risk for depression, and depression and T2D are linked. Depressive symptoms are a risk factor for worsening of insulin sensitivity, one if the major precursors to T2D. In preliminary studies, the investigators found that a brief cognitive-behavioral therapy group decreased depressive symptoms and prevented worsening of insulin sensitivity in adolescent girls at-risk for T2D with moderate depressive symptoms. The aims of this study are: 1) to assess the efficacy of a cognitive-behavioral therapy depression group vs. a health education control group for improving insulin sensitivity and preserving insulin secretion in racially/ethnically diverse adolescent girls at-risk for T2D with moderate depressive symptoms over a 1-year follow-up; 2) to evaluate changes in eating, physical activity, and sleep as explanatory and 3) to test changes in cortisol factors as explanatory.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:12 - 17
Sex:Female

147 Participants Needed

Whole Health Intervention for PTSD

Aurora, Colorado
This trial tests Omnis Salutis, a program for recent veterans of the Afghanistan and Iraq conflicts. The program helps veterans set and share their health goals with doctors and support systems to improve their well-being.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65

238 Participants Needed

1234

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Depression clinical trials in Salt Lake City, UT pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Depression clinical trials in Salt Lake City, UT work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Depression trials in Salt Lake City, UT 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Salt Lake City, UT for Depression is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Salt Lake City, UT several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Depression medical study in Salt Lake City, UT?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Depression clinical trials in Salt Lake City, UT?

Most recently, we added Collaborative Decision Skills Training for Serious Mental Illness, Morphine or Ketamine for Pain and Technology Assisted Collaborative Care for Chronic Kidney Disease to the Power online platform.

What do the "Power Preferred" and "SuperSite" badges mean?

We recognize research clinics with these awards when they are especially responsive to patients who apply through the Power online platform. SuperSite clinics are research sites recognized for a high standard of rapid and thorough follow-up with patient applicants. Meanwhile, Power Preferred clinics are the top 20 across the entire Power platform, recognized for their absolute top patient experience.

Which clinics have received Power Preferred and SuperSite awards recruiting for Depression trials in Salt Lake City, UT?

The Depression clinics in Salt Lake City, UT currently recognized as Power Preferred are: Cedar Clinical Research in Murray, Utah Cedar Clinical Research in Draper, Utah Cedar Clinical Research in Draper, Utah Redbird Research in Las Vegas, Nevada Red Bird Research in Las Vegas, Nevada Red Bird Research in Las Vegas, Nevada IMA Albuquerque in Albuquerque, New Mexico IMA Albuquerque in Albuquerque, New Mexico IMA Clinical Research in Phoenix, Arizona IMA Phoenix in Phoenix, Arizona IMA Phoenix in Phoenix, Arizona IMA Clinical Research Phoenix in Phoenix, Arizona IMA Phoenix in Phoenix, Arizona IMA Phoenix in Phoenix, Arizona Anderson Clinical Research in Redlands, California Anderson Clinical Research in Redlands, California Viking Clinical Research in Temecula, California Sunwise Clinical Research in Walnut Creek, California Sunwise Clinical Research, LLC in Walnut Creek, California Sunwise Clinical Research in Lafayette, California

What are the current treatment options for depression?

Doctors use a stepped-care approach. First, most people try evidence-based talk therapy (such as CBT or interpersonal therapy), an antidepressant medicine (SSRIs are typical), or both, while also improving sleep, exercise and diet. If symptoms persist, the next “step” is to add or switch treatments—e.g., combining two medicines, adding lithium or an antipsychotic, or using brain-stimulation methods like transcranial magnetic stimulation or, for severe cases, electroconvulsive therapy; newer options such as esketamine nasal spray are reserved for treatment-resistant depression. Working with a clinician to review progress every few weeks and adjust the plan is key to finding the right mix.

When is depression considered severe?

Doctors call a depressive episode “severe” when almost all of the nine core symptoms are present at high intensity, the person’s daily life has largely shut down (can’t work, study, or manage self-care), or there are high-risk features like active suicidal thoughts, a recent attempt, or hallucinations/false beliefs. On common checklists this usually means a PHQ-9 score of 20 or higher, and it signals the need for urgent, comprehensive care—often a combination of medication, psychotherapy, and sometimes hospitalization. If you or someone you know reaches this point, treat it as an emergency and contact a mental-health professional or call/text 988 (USA) or your local crisis line right away.

Is it possible to never be depressed again?

Some people have a single episode of depression and stay well, but the risk of another episode is higher if you stop treatment too soon, have had several episodes before, or still have mild symptoms. You can greatly lower that risk by continuing the treatment that got you better for at least 6–12 months, learning relapse-prevention skills in CBT or mindfulness therapy, keeping regular sleep, exercise, and social routines, and checking in early with a professional if warning signs return. In short, there is no iron-clad guarantee you’ll never be depressed again, but staying on maintenance care and a healthy lifestyle makes long-term wellness much more likely.

What are the top 3 symptoms of depression?

Doctors look first for three core signs: 1) a low or hopeless mood that hangs around most of the day, nearly every day; 2) a marked loss of interest or pleasure in things you used to enjoy (called anhedonia); and 3) big changes in body energy—feeling drained, sleeping or eating far more or less than usual. If any of these have lasted two weeks or longer, it’s time to talk with a health professional, because other symptoms can pile on and treatment works best when started early.

Is depression a chemical imbalance?

No—depression can’t be pinned on one missing brain chemical. Research shows it arises from a mix of factors: how your brain circuits and several neurotransmitters work, your genes, long-term stress, and life circumstances all interact. Because causes differ from person to person, the most effective care is usually a combination of approaches—medication when needed, talking therapies, and lifestyle changes—worked out with your clinician.

How many people have untreatable depression?

Doctors call “untreatable” depression “treatment-resistant depression,” meaning the person has not improved after trying at least two suitable antidepressants. Large studies show this applies to roughly one-quarter to one-third of people with major depression—about 2–3 % of adults overall, or roughly 5–8 million U.S. adults in any given year. Importantly, many still respond to other options such as medication combinations, ketamine/esketamine, transcranial magnetic stimulation, or electroconvulsive therapy.

How to get out of deep depression?

Think of recovery as two tracks that run side-by-side. Track 1: get professional help right away—if you ever feel unsafe call 988 (or your local hotline), and with a clinician discuss proven treatments such as CBT, antidepressant medicine, and, when needed, newer options like ketamine, transcranial magnetic stimulation or electroconvulsive therapy. Track 2: reinforce the medical plan daily with mood-boosting basics—consistent exercise, regular sleep, balanced meals, limited alcohol or drugs, and time with supportive people—because these habits make the treatments work better and give you small, sustainable lifts while you heal.

Why is depression so hard to treat?

Depression is hard to treat because it isn’t a single disease—each person’s symptoms arise from a unique blend of brain chemistry, genetics, stress, medical issues, and life circumstances—so one-size-fits-all therapies rarely work. Without a blood test to guide choices, clinicians must try treatments sequentially, and roughly one-third of people need several steps or a combination of medication, talk therapy, lifestyle changes, or newer options like ketamine or magnetic stimulation before they feel well. The encouraging news is that persistence with a systematic plan and attention to sleep, exercise, and co-existing conditions allows most patients to eventually reach full recovery.

What are unhealthy coping mechanisms for depression?

Unhealthy coping means doing things that give quick relief but actually deepen depression—common examples include using alcohol or other drugs, overeating or not eating, oversleeping or endless screen-scrolling to avoid feelings, cutting or other self-harm, harsh self-talk and rumination, and withdrawing from friends or lashing out at them. These behaviors worsen mood, relationships, and safety; if you notice yourself relying on them, reach out to a trusted person or mental-health professional (or call your local crisis line) and ask about safer skills such as problem-solving steps, scheduled activity, or therapy.

Is it OK to have clinical depression?

Yes—having clinical depression isn’t a personal failing; it’s a common medical illness, and recognising it is the first step toward feeling better. What isn’t OK is to face it alone, because untreated depression can worsen and raise the risk of other problems, whereas most people improve with timely care such as talk therapy, medication, or a combination. If symptoms last more than two weeks or include thoughts of self-harm, book a visit with a primary-care doctor or mental-health professional and, in crisis, call 988 (U.S.) or your local emergency number—effective help and recovery are the norm when treatment is started.

Popular Searches

By Condition

Depression Clinical Trials in Utah

Anxiety Clinical Trials in Utah

Schizophrenia Clinical Trials in Utah

ADHD Clinical Trials in Utah

Bipolar Disorder Clinical Trials in Utah

Multiple Sclerosis Clinical Trials in Utah

Autism Clinical Trials in Utah

Treatment Resistant Depression Clinical Trials in Utah

Borderline Personality Disorder Clinical Trials in Utah

Social Anxiety Disorder Clinical Trials in Utah

Parkinson's Disease Clinical Trials in Utah

Alzheimer's Disease Clinical Trials in Utah

By Location

Clinical Trials near Salt Lake City, UT

Clinical Trials near Murray, UT

Clinical Trials near Ogden, UT

Clinical Trials near West Jordan, UT

Clinical Trials near Saint George, UT

Clinical Trials near Provo, UT

Clinical Trials near Layton, UT

Clinical Trials near South Jordan, UT

Clinical Trials near Logan, UT

Clinical Trials near Bountiful, UT

Clinical Trials near Draper, UT

Clinical Trials near Orem, UT

Other People Viewed

By Subject

83 Diabetes Trials near Provo, UT

199 Clinical Trials near Kaysville, UT

215 Clinical Trials near Bountiful, UT

211 Clinical Trials near Farmington, UT

132 Clinical Trials near Cedar City, UT

86 Depression Trials near Jacksonville, FL

36 Depression Trials near Round Rock, TX

177 Clinical Trials near Jersey City, NJ

Top Clinical Trials near Salt Lake City, UT

Top Clinical Trials near Draper, UT

Top Depression Clinical Trials near Kansas City, MO

Top Clinical Trials near Avon Lake, OH

By Trial

Ketamine-Assisted Psychotherapy for Depression

ACT + Ketamine for Alcoholism and Depression

Rumination-Focused Cognitive Behavioural Therapy for Depression

Seltorexant for Depression

Cognitive Training + Ketamine for Depression

Transcutaneous Auricular Vagus Nerve Stimulation for Depression

Ketamine Imaging for Mood Disorders

GLP-1 for Low Blood Sugar

Curcumin, Omega-3, and Vitamin D Supplements for Healthy Subjects

Deep Brain Stimulation for Treatment-Resistant Depression

Bupropion for Fatigue in Breast Cancer Survivors

Topical Imipramine Cream for Photosensitivity

Related Searches

Top Depression Clinical Trials near San Jose, CA

Top Depression Clinical Trials near Scottsdale, AZ

Top Depression Clinical Trials near Seattle, WA

Top Depression Clinical Trials near Tucson, AZ

Top Depression Clinical Trials near Washington Dc, DC

Top Depression Clinical Trials near West Palm Beach, FL

Top Diabetes Clinical Trials near Fort Lauderdale, FL

Top Liposarcoma Clinical Trials

Prophylactic Tamsulosin for Urinary Retention After Colorectal Surgery

CMV-Specific CTLs for CMV Infection

Rifaximin for Dementia

Nonpharmacologic Strategies for Chronic Pain

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial